Patent application number | Description | Published |
20100063059 | NOVEL PYRIDAZINE COMPOUND AND USE THEREOF - A compound of formula (1) and its salts and solvates are provided for the treatment or prophylaxis of hepatitis C virus infections. Methods of making and formulating compound (1) are provided. | 03-11-2010 |
20130136776 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS C VIRUS - Disclosed herein are a composition and unit dosage form for the treatment of hepatitis C virus (HCV) infection comprising GS-7977 and at least one pharmaceutically acceptable excipient, as well as methods for making said composition and unit dosage form. Also disclosed herein is a method of treating a subject, preferably a human, infected with hepatitis C virus, said method comprising administering to the subject for a time period an effective amount of GS-7977 and an effective amount of ribavirin. In one aspect, the method comprises administering to the subject an interferon-free treatment regimen comprising an effective amount of GS-7977 and an effective amount of ribavirin. In a particular aspect, the method is sufficient to produce an undetectable amount of HCV RNA in the subject for at least 12 weeks after the end of the time period. | 05-30-2013 |
20130243857 | THERAPEUTIC COMPOSITIONS COMPRISING RILPIVIRINE HCL AND TENOFOVIR DISOPROXIL FUMARATE - The invention provides multilayer tablets that contain rilpivirine hydrochloride, emtricitabine, and tenofivir disoproxil fumarate. The tablets are useful for the treatment of HIV. | 09-19-2013 |
20140037732 | METHOD AND COMPOSITION FOR PHARMACEUTICAL PRODUCT - This invention is directed to a composition comprising dry granulated tenofovir DF and emtricitabine, and a method for making same. Dry granulation was unexpectedly found to be important in preparing a tenofovir DF containing composition suitable for inclusion in a combination dosage form containing emtricitabine, efavirenz and tenofovir DF. | 02-06-2014 |
20140212487 | SOLID DISPERSION FORMULATION OF AN ANTIVIRAL COMPOUND - Disclosed are solid dispersions comprising ledipasvir, wherein ledipasvir is dispersed within a polymer matrix formed by a pharmaceutically acceptable polymer, and further wherein ledipasvir is substantially amorphous. Also disclosed are pharmaceutical compositions comprising solid dispersion and methods of using the solid dispersion. | 07-31-2014 |
20140212491 | COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS - Disclosed are pharmaceutical compositions having an effective amount of substantially amorphous ledipasvir and an effective amount of substantially crystalline sofosbuvir. | 07-31-2014 |
20140370102 | METHOD AND COMPOSITION FOR PHARMACEUTICAL PRODUCT - This invention is directed to a composition comprising dry granulated tenofovir DF and emtricitabine, and a method for making same. Dry granulation was unexpectedly found to be important in preparing a tenofovir DF containing composition suitable for inclusion in a combination dosage form containing emtricitabine, efavirenz and tenofovir DF. | 12-18-2014 |
20150064252 | SOLID DISPERSION FORMULATION OF AN ANTIVIRAL COMPOUND - Disclosed are solid dispersions comprising a compound having the formula: | 03-05-2015 |
20150064253 | COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS - Disclosed are pharmaceutical compositions comprising Compound I, having the formula: | 03-05-2015 |